What is Finch Therapeutics Group Inc?
, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 21.46M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.